IDH1 and neoplasm: Targeting G6PD and other metabolic regulators, such as pyruvate kinase isozymes M1/M2 (PKM1/2), monocarboxylate transporter (MCT), and isocitrate dehydrogenase 1/2 (IDH1/2), has attracted attention as a potential anti-tumor therapeutic strategy [167].